Core Viewpoint - Novo Nordisk has officially launched the injectable product, Pegylated Coagulation Factor VIII (brand name: Nuwiq), in mainland China, marking it as the only approved long-acting recombinant factor VIII in the country, which has been included in the new national medical insurance catalog [1] Group 1: Product Launch and Market Impact - The launch of Nuwiq fills a significant gap in long-term treatment options for Hemophilia A in China, enhancing medication accessibility for patients and ushering them into a new treatment phase [1] - Hemophilia A, characterized by a deficiency of coagulation factor VIII, accounts for approximately 80%-85% of all hemophilia cases, necessitating lifelong treatment to prevent severe health consequences [1] Group 2: Clinical Data and Efficacy - Since its approval in the United States in 2019, Nuwiq has accumulated extensive efficacy and safety data for the prevention and treatment of bleeding globally [1] - In a multi-center trial (Pathfinder105) conducted among Chinese Hemophilia A patients, the median annualized bleeding rate (ABR) for those receiving preventive treatment with Nuwiq was 0.00, with a 69.4% rate of zero bleeding patients and a 94.8% success rate in stopping bleeding episodes [1]